Scientists identified new molecular pathways through which lithium chloride may interact with mechanisms underlying Alzheimer’s disease.
Alzheimer’s disease involves accumulation of abnormal proteins and progressive loss of cognitive function.
Lithium compounds have been studied for potential neuroprotective effects in various brain disorders.
Researchers mapped how lithium chloride influences signaling and protein processing linked to Alzheimer’s pathology.
The pathways differ from those targeted by currently approved Alzheimer’s medications.
Laboratory models showed changes in markers associated with amyloid and tau biology.
Lithium is widely prescribed for bipolar disorder, but brain concentrations from those doses differ from experimental protocols.
Scientists cautioned that pathway identification in cells does not prove clinical benefit in patients.
Alzheimer’s affects millions worldwide, driving intense search for disease-modifying treatments.
Further preclinical work will test whether lithium chloride can safely alter the identified pathways in living models.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/